Literature DB >> 7724492

Acute renal toxicity of doxorubicin (adriamycin)-loaded cyanoacrylate nanoparticles.

L Manil1, P Couvreur, P Mahieu.   

Abstract

Acute doxorubicin-loaded nanoparticle (DXNP) renal toxicity was explored in both normal rats and rats with experimental glomerulonephritis. In normal rats, 2/6 rats given free doxorubicin (DX) (5 mg/kg) died within one week, whereas all control animals and all rats having received free NP or DXNP survived. A 3 times higher proteinuria appeared in animals treated with DXNP than in those treated with DX. Free NP did not provoke any proteinuria. Two hr post-injection, DXNP was 2.7 times more concentrated in kidneys than free DX (p < 0.025). In rats with immune experimental glomerulonephritis, 5/6 rats given DX died within 7 days, in contrast to animals treated by DXNP, NP, or untreated, which all survived. Proteinuria appeared in all series, but was 2-5 times more intense (p > 0.001) and prolonged after doxorubicin treatment (400-700 mg/day), without significant difference between DXNP and DX. Rats treated by unloaded NP behaved as controls. These results demonstrate that, in these experimental conditions, DXNP killed less animals than free DX, despite of an enhanced renal toxicity of the former. Both effects (better survival and nephrosis) are most probably related to an enhanced capture of DXNP by cells of the mononuclear phagocyte system, including mesangial cells.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7724492     DOI: 10.1023/a:1016290704772

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  10 in total

1.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

2.  Polycyanoacrylate nanocapsules as potential lysosomotropic carriers: preparation, morphological and sorptive properties.

Authors:  P Couvreur; B Kante; M Roland; P Guiot; P Bauduin; P Speiser
Journal:  J Pharm Pharmacol       Date:  1979-05       Impact factor: 3.765

3.  Adsorption of antineoplastic drugs to polyalkylcyanoacrylate nanoparticles and their release in calf serum.

Authors:  P Couvreur; B Kante; M Roland; P Speiser
Journal:  J Pharm Sci       Date:  1979-12       Impact factor: 3.534

4.  Toxicity of polyalkylcyanoacrylate nanoparticles II: Doxorubicin-loaded nanoparticles.

Authors:  P Couvreur; B Kante; L Grislain; M Roland; P Speiser
Journal:  J Pharm Sci       Date:  1982-07       Impact factor: 3.534

5.  Hepatic tissue distribution of doxorubicin-loaded nanoparticles after i.v. administration in reticulosarcoma M 5076 metastasis-bearing mice.

Authors:  N Chiannilkulchai; N Ammoury; B Caillou; J P Devissaguet; P Couvreur
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

6.  Tubulo-interstitial lesions mediate renal damage in adriamycin glomerulopathy.

Authors:  T Bertani; F Cutillo; C Zoja; M Broggini; G Remuzzi
Journal:  Kidney Int       Date:  1986-10       Impact factor: 10.612

7.  Doxorubicin-loaded nanospheres bypass tumor cell multidrug resistance.

Authors:  C Cuvier; L Roblot-Treupel; J M Millot; G Lizard; S Chevillard; M Manfait; P Couvreur; M F Poupon
Journal:  Biochem Pharmacol       Date:  1992-08-04       Impact factor: 5.858

8.  Uptake of nanoparticles by rat glomerular mesangial cells in vivo and in vitro.

Authors:  L Manil; J C Davin; C Duchenne; C Kubiak; J Foidart; P Couvreur; P Mahieu
Journal:  Pharm Res       Date:  1994-08       Impact factor: 4.200

9.  Adriamycin-induced nephropathy as a model of chronic progressive glomerular disease.

Authors:  S Okuda; Y Oh; H Tsuruda; K Onoyama; S Fujimi; M Fujishima
Journal:  Kidney Int       Date:  1986-02       Impact factor: 10.612

10.  A mononuclear cell component in experimental immunological glomerulonephritis.

Authors:  G F Schreiner; R S Cotran; V Pardo; E R Unanue
Journal:  J Exp Med       Date:  1978-02-01       Impact factor: 14.307

  10 in total
  7 in total

Review 1.  Best practices in cancer nanotechnology: perspective from NCI nanotechnology alliance.

Authors:  William C Zamboni; Vladimir Torchilin; Anil K Patri; Jeff Hrkach; Stephen Stern; Robert Lee; Andre Nel; Nicholas J Panaro; Piotr Grodzinski
Journal:  Clin Cancer Res       Date:  2012-06-05       Impact factor: 12.531

2.  Translational considerations for cancer nanomedicine.

Authors:  Stephan T Stern; Jennifer B Hall; Lee L Yu; Laura J Wood; Giulio F Paciotti; Lawrence Tamarkin; Stephen E Long; Scott E McNeil
Journal:  J Control Release       Date:  2010-04-10       Impact factor: 9.776

Review 3.  Medicinal plants and cancer chemoprevention.

Authors:  Avni G Desai; Ghulam N Qazi; Ramesh K Ganju; Mahmoud El-Tamer; Jaswant Singh; Ajit K Saxena; Yashbir S Bedi; Subhash C Taneja; Hari K Bhat
Journal:  Curr Drug Metab       Date:  2008-09       Impact factor: 3.731

4.  Botanical from Piper capense Fruit Can Help to Combat the Melanoma as Demonstrated by In Vitro and In Vivo Studies.

Authors:  Brice E N Wamba; Paramita Ghosh; Armelle T Mbaveng; Sayantan Bhattacharya; Mitra Debarpan; Saha Depanwita; Mustafi Mitra Saunak; Victor Kuete; Nabendu Murmu
Journal:  Evid Based Complement Alternat Med       Date:  2021-01-18       Impact factor: 2.629

5.  Asialoglycoprotein receptor targeted delivery of doxorubicin nanoparticles for hepatocellular carcinoma.

Authors:  Sandhya Pranatharthiharan; Mitesh D Patel; Vinod C Malshe; Vaishali Pujari; Ajit Gorakshakar; Manisha Madkaikar; Kanjaksha Ghosh; Padma V Devarajan
Journal:  Drug Deliv       Date:  2017-11       Impact factor: 6.419

6.  Enhanced antitumor efficacy and reduced systemic toxicity of sulfatide-containing nanoliposomal doxorubicin in a xenograft model of colorectal cancer.

Authors:  Jia Lin; Yan Yu; Sarah Shigdar; Ding Zhi Fang; Jun Rong Du; Ming Q Wei; Andrew Danks; Ke Liu; Wei Duan
Journal:  PLoS One       Date:  2012-11-07       Impact factor: 3.240

7.  Nanotechnology-based detection and targeted therapy in cancer: nano-bio paradigms and applications.

Authors:  Shaker A Mousa; Dhruba J Bharali
Journal:  Cancers (Basel)       Date:  2011-07-15       Impact factor: 6.639

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.